Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerging Markets Earnings Roundup: AstraZeneca And Roche (Part 4)

This article was originally published in PharmAsia News

Executive Summary

Although AstraZeneca achieved 17% growth in China for 2012, there is room for improvement, CEO Pascal Soriot told investors. Meanwhile, Soriot’s old company Roche seems to be discussing emerging markets less on its quarterly calls since he left, but nevertheless ramps up sales for key products Avastin and Herceptin.

You may also be interested in...



On Soriot’s List For AstraZeneca: Building A Decision-Making Culture

AstraZeneca investors will have to wait two more months to hear details of CEO Pascal Soriot’s plans for re-energizing the struggling big pharma. But the new chief did discuss several near-term objectives for the company and what he has pinpointed as being some of the operational problems, based on discussion with hundreds of employees, during a year-end financial call Jan. 31.

Roche’s Oncology Output Could Lead To Reimbursement Problems Down The Line

Roche posted solid 2012 results and development of new cancer drugs continues apace, forecasting further sales and profit gains in 2013 and beyond – as long as government insurers can handle the abundance.

Cold Water On Already Frozen Sector: Industry Growing Wary Of China Price Cuts

From orphan to cancer drugs, more products have had their prices cut in the latest round of reimbursement negotiations in China. Although the 60% average across 100 medicines was considered mild given it didn’t go beyond the previous year, it was still chilling and is prompting more firms, both multinational and domestic, to walk away from the process.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC083650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel